LINC00113: A Drug Target / Disease Biomarker (G54088)

Target Name: LINC00113

NCBI ID: G54088

Other Name(s): SLERCC | NCRNA00113 | C21orf23 | Long intergenic non-protein coding RNA 113 | long intergenic non-protein coding RNA 113

LINC00113: A Drug Target / Disease Biomarker

LINC00113 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target for various diseases.

LINC00113 is a transmembrane protein that is composed of four intracellular domains: an N-terminal transmembrane domain, a coiled-coil domain, a regulatory domain, and an C-terminal T-spine domain. The N-terminal transmembrane domain is responsible for the protein's ability to enter the cell membrane and for its ability to interact with other proteins. The coiled-coil domain is responsible for the protein's ability to change shape and to play a role in cell signaling. The regulatory domain is responsible for the protein's ability to regulate gene expression, and the C-terminal T-spine domain is responsible for the protein's structural stability.

LINC00113 is a key regulator of cell growth and differentiation. It is involved in the regulation of cell proliferation, cell migration, and cell adhesion. LINC00113 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising aspects of LINC00113 as a drug target is its ability to modulate the activity of other proteins. LINC00113 has been shown to interact with a wide range of proteins, including transcription factors, signaling molecules, and cytoskeletal proteins. This makes it a potential target for drugs that can modulate the activity of these proteins and improve treatment outcomes for various diseases.

LINC00113 has also been shown to play a role in the regulation of cellular signaling pathways. LINC00113 has been shown to interact with the protein p53, a transcription factor that is involved in the regulation of gene expression and cell survival. This interaction between LINC00113 and p53 suggests that LINC00113 may be a useful target for drugs that can modulate the activity of p53 and improve treatment outcomes for various diseases.

Another promising aspect of LINC00113 as a drug target is its ability to modulate the activity of the immune system. LINC00113 has been shown to interact with the protein PDGF-R, a cytoskeletal protein that is involved in the regulation of cell growth and differentiation. This interaction between LINC00113 and PDGF-R suggests that LINC00113 may be a useful target for drugs that can modulate the activity of PDGF-R and improve immune function.

In conclusion, LINC00113 is a protein that has been identified as a potential drug target for various diseases. Its ability to modulate the activity of other proteins and play a role in the regulation of cellular signaling pathways and immune function makes it a promising target for future drug development. Further research is needed to fully understand the role of LINC00113 as a drug target and to develop effective treatments for various diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 113

More Common Targets